target icon View trials by
therapeutic target
phase icon View trials
by phase
cancer type icon View trials by
cancer type

B-Cell Lymphoma 2 (BCL-2)

Enrolling
Advanced Hematologic Malignancies
LOXO-338

Bruton's Tyrosine Kinase (BTK)

Enrolling
CLL/SLL
Pirtobrutinib (LOXO-305)
Enrolling
CLL/SLL
Pirtobrutinib (LOXO-305)
Enrolling
CLL/SLL
Pirtobrutinib (LOXO-305)
Enrolling
CLL/SLL or NHL
Pirtobrutinib (LOXO-305)
Enrolling
MCL
Pirtobrutinib (LOXO-305)

CDK4 & 6

Breast Cancer
Abemaciclib
Breast Cancer
Abemaciclib
Enrolling
Enrolling
Pediatric Cancer
Abemaciclib
Enrolling
Prostate Cancer
Abemaciclib
Prostate Cancer
Abemaciclib
Enrolling
Prostate Cancer
Abemaciclib

Isocitrate Dehydrogenase 1/2 (IDH1/2)

Enrolling
Advanced Hematologic Malignancies
LY3410738
Enrolling
Advanced Solid Tumors
LY3410738

Kirsten Rat Sarcoma Viral Oncogene (KRAS) G12C

Enrolling
Colorectal Cancer, NSCLC, or Other Advanced Solid Tumors
LY3537982

PI3Kα Inhibitor

Enrolling
Advanced Solid Tumors
LOXO-783

Next-Generation Rearranged During Transfection (Next-Gen RET)

Enrolling
Lung Cancer, Medullary Thyroid Cancer, or Other Advanced Solid Tumors
LOXO-260

Programmed Cell Death Protein 1 (PD-1)

Rearranged During Transfection (RET)

Enrolling
Medullary Thyroid Cancer
Selpercatinib
Enrolling
Enrolling
Enrolling
NSCLC, Medullary Thyroid Cancer, Papillary Thyroid Carcinoma, or Other Advanced Solid Tumors
Selpercatinib
Enrolling
Pediatric Cancer
Selpercatinib

Selective Estrogen Receptor Degrader (SERD)

Enrolling
Breast Cancer or Endometrial Cancer
Imlunestrant
Enrolling
Enrolling

Vascular Endothelial Growth Factor Receptor-2 (VEGFR2)

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.